---
url: https://www.servicesaustralia.gov.au/severe-asthma-toxicity-and-severity-descriptors
title: Severe asthma toxicity and severity descriptors - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:43:59.077Z
source: servicesaustralia.gov.au
---
# Severe asthma toxicity and severity descriptors

Toxicity criteria and severity descriptors for treatments required to be trialled before accessing PBS-subsidised biological medicines to treat severe asthma.

## on this page

-   [Inhaled corticosteroids](#a1)
-   [Inhaled beta-2 agonists](#a2)
-   [Oral Corticosteroids](#a3)

ADL - activities of daily living  
NIH - National Institutes of Health  
LLN - lower limit of normal  
ULN - upper limit of normal

## Inhaled corticosteroids

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Gastro-intestinal**

Diarrhoea

Increase of 4 to 6 stools/day over baseline

2 (or higher)

Nausea

Oral intake decreased without significant weight loss, dehydration or malnutrition

2 (or higher)

Weight gain

≥ 20% weight gain from baseline

3 (or higher)

**Nervous system - past psychiatric history not a contraindication**

Anxiety

Moderate symptoms; limiting instrumental ADL

2 (or higher)

Headaches

Moderate pain; limiting instrumental ADL

2 (or higher)

Insomnia

Moderate difficulty in falling asleep, staying asleep or waking up early

2 (or higher)

Mood alteration

Moderate mood alteration; limiting instrumental ADL

2 (or higher)

**Dermatological**

Rash

Macules, papules, urticaria or exanthem, with or without associated symptoms, covering > 30% of body surface area; limiting self-care ADL

3 (or higher)

Purpura/bruising

Combined area of lesion covering 10 - 30% body surface area; bleeding with trauma

2 (or higher)

**Endocrine**

Adrenal insufficiency/suppression

Moderate symptoms; medical intervention indicated

2 (or higher)

Cushingoid

Moderate symptoms; medical intervention indicated

2 (or higher)

Hyperglycaemia

Fasting glucose value > 8.9 mmol/L

2 (or higher)

**Ocular**

Cataracts

Symptomatic; moderate decrease in visual acuity (20/40 or better)

2 (or higher)

Glaucoma

Elevated intraocular pressure causing early visual field deficits; multiple topical or oral agents indicated; limiting instrumental ADL

2 (or higher)

**Musculoskeletal**

Growth suppression

Reduction in growth velocity by 10-29% ideally measured over the period of a year

1 (or higher)

Myalgia/cramp

Moderate pain: limiting instrumental ADL

2 (or higher)

Osteoporosis

BMD t-score < -2.5; loss of height < 2 cm; anti-osteoporotic therapy indicated; limiting instrumental ADL

2 (or higher)

**Respiratory**

Bronchospasm (paradoxical)

Symptomatic; medical intervention indicated; limiting instrumental ADL

2 (or higher)

Cough

Severe symptoms; limiting self-care ADL

3 (or higher)

Epistaxis

Moderate symptoms; medical intervention indicated (e.g. nasal packing, cauterisation, topical vasoconstrictors)

2 (or higher)

Hoarseness

Moderate or persistent voice changes; may require occasional repetition but understandable on telephone; medical evaluation indicated

2 (or higher)

**Miscellaneous**

Anaphylaxis/Hypersensitivity

Symptomatic bronchospasm, with or without urticaria; parenteral intervention indicated; allergy related oedema / angioedema; hypotension

3 (or higher)

## Inhaled beta-2 agonists

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Gastro-intestinal**

Diarrhoea

Increase of 4 to 6 stools/day over baseline

2 (or higher)

Nausea

Oral intake decreased without significant weight loss, dehydration or malnutrition

2 (or higher)

Vomiting

3 or more episodes (separated by 5 minutes) in 24 hours over baseline

2 (or higher)

**Cardiovascular**

Cardiac arrhythmia

Medical intervention indicated

3 (or higher)

**Nervous system - past psychiatric history not a contraindication**

Mood alteration

Moderate mood alteration; limiting instrumental ADL

2 (or higher)

Anxiety

Moderate symptoms; limiting instrumental ADL

2 (or higher)

Headaches

Moderate pain; limiting instrumental ADL

2 (or higher)

Insomnia

Severe difficulty in falling asleep, staying asleep or waking up early

3 (or higher)

Tremor

Moderate symptoms; limiting instrumental ADL

2 (or higher)

**Dermatological**

Rash

Macules, papules, urticaria or exanthem, with or without associated symptoms, covering > 30% of body surface area; limiting self-care ADL

3 (or higher)

**Musculoskeletal**

Myalgia/cramp

Moderate pain: limiting instrumental ADL

2 (or higher)

**Metabolism**

Hypokalemia

< LLN - 3.0 mmol/L; symptomatic; intervention indicated

2 (or higher)

**Respiratory**

Bronchospasm (paradoxical)

Symptomatic; medical intervention indicated; limiting instrumental ADL

2 (or higher)

**Miscellaneous**

Anaphylaxis/Hypersensitivity

Symptomatic bronchospasm, with or without urticaria; parenteral intervention indicated; allergy related oedema / angioedema; hypotension

3 (or higher)

## Oral Corticosteroids

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Gastro-intestinal**

Gastric irritation/ulcer

Symptomatic; altered GI function; medical intervention indicated; limiting instrumental ADL

2 (or higher)

Nausea

Oral intake decreased without significant weight loss, dehydration or malnutrition

2 (or higher)

Vomiting

3 or more episodes (separated by 5 minutes) in 24 hours over baseline

2 (or higher)

Weight gain

≥ 20% weight gain from baseline

3 (or higher)

**Cardiovascular**

Hypertension

Stage 2 hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg); requiring medical intervention; more intensive therapy than previously used

3 (or higher)

Fluid retention

Symptomatic; limiting function, unresponsive to therapy or requiring drug discontinuation

3 (or higher)

Heart failure

Severe with symptoms at rest or with minimal activity or exertion; intervention indicated

3 (or higher)

**Nervous system - past psychiatric history not a contraindication**

Insomnia

Severe difficulty in falling asleep, staying asleep or waking up early

3 (or higher)

Mood alteration

Severe mood alteration interfering with ADL

3 (or higher)

Personality/behavioural

Disruptive to patient/family, requiring mental health intervention

3 (or higher)

Restlessness

Severe symptoms; limiting self-care ADL

3 (or higher)

**Dermatological**

Acne/dermatological conditions

Severe

3 (or higher)

Purpura/bruising

Combined area of lesion covering 10-30% body surface area; bleeding with trauma

2 (or higher)

Impaired healing

Requiring medical management

2 (or higher)

**Laboratory**

Hypertriglyceridemia

< 5.7 mmol/L

3 (or higher)

Hypokalemia

< 3.0 mmol/L; hospitalisation indicated

3 (or higher)

**Endocrine**

Glucose intolerance

Symptomatic; diet modification or oral agent indicated

2 (or higher)

Hyperglycaemia

Fasting glucose value > 8.9 mmol/L

2 (or higher)

Disordered menstruation

Very irregular over pre-treatment

2 (or higher)

**Ocular**

Cataracts

Symptomatic with marked decrease in visual acuity (worse than 20/40 but better than 20/200); operative intervention indicated (eg cataract surgery)

3 (or higher)

Glaucoma

Elevated intraocular pressure causing early visual field deficits; multiple topical or oral agents indicated; limiting instrumental ADL

2 (or higher)

**Musculoskeletal**

Osteoporosis or fracture

Symptomatic, interfering with ADL

 

Avascular necrosis

Symptomatic; limiting instrumental ADL

2 (or higher)

Myopathy

Symptomatic; evident on physical exam; limiting instrumental ADL

2 (or higher)

Infections and infestations

Severe or medically significant but not immediately life threatening; limiting self-care ADL

3 (or higher)

**Miscellaneous**

Immunosuppression

Severe; requiring treatment withdrawal
